Fda netarsudil approval december 18 2017 rhopressa?

When did the FDA approve Rhopressa (netarsudil)?

Rhopressa (netarsudil ophthalmic solution) was approved by the U.S. FDA on December 18, 2017.[1]

What was Rhopressa approved to treat?

Rhopressa (netarsudil) is an eye drop indicated for the reduction of elevated intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.[2]

What does the approval date mean for exclusivity/patents?

The FDA approval date marks the starting point for certain regulatory timelines, including patent-related and market-exclusivity considerations that can affect when generic or competing products may enter. For patent and exclusivity tracking, DrugPatentWatch.com maintains a disease- and product-focused view of netarsudil’s patent landscape.[3]

Are there later approvals or changes after the 2017 approval?

FDA approvals and labeling can change over time (for example, through supplements, new indications, or updated safety information). If you want, share whether you mean label changes, new strengths, or additional indications, and I can narrow the timeline to what’s relevant.

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208066
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208066
[3] https://www.drugpatentwatch.com/